Skip to Main Content

5,461

Views

23

CrossRef citations to date

0

Altmetric

Articles

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

K. Reicha Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Skinflammation Center, Hamburg and Dermatologikum Berlin, Berlin, GermanyView further author information

,

A. M. DeLozierb Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

F. P. Nunesb Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

J. P. Thyssenc Department of Dermatology and Allergy, Herlev and Gentofte Hospital and University of Copenhagen, Copenhagen, DenmarkView further author information

,

L. F. Eichenfieldd Departments of Dermatology and Pediatrics, University of California, San Diego and Rady Children’s Hospital, San Diego, CA, USAView further author information

,

A. Wollenberge Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, GermanyView further author information

,

J. A. Ross Terresb Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

S. D. Wattsb Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

Y.-F. Chenb Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

E. L. Simpsonf Department of Dermatology, Oregon Health and Science University, Portland, OR, USAView further author information

&

J. I. Silverbergg Department of Dermatology, George Washington University School of Medicine, Washington, DC, USACorrespondence[email protected]
View further author information